IgA型多发性骨髓瘤患者预后因素分析

刘婷利; 李护君; 姚瑶; 姚若斯; 徐开林; 李振宇

doi:10.13201/j.issn.1004-2806.2019.01.008

IgA型多发性骨髓瘤患者预后因素分析

- 徐州医科大学附属医院血液科(江苏徐州, 221002)
基金项目:
国家自然科学基金 (No:8177011264、8157010416)

江苏省医学重点人才 (No:ZDRCA2016052)

详细信息

通讯作者: 李振宇,E-mail:lizhenyumd@163.com

中图分类号: R733.3

收稿日期: 2018-10-14

Analysis of prognostic factors in patients with IgA type multiple myeloma

- Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China

More Information

Corresponding author: LI Zhenyu, E-mail: lizhenyumd@163.com

Received Date: 14 October 2018

摘要

摘要: 目的:探究初诊IgA型多发性骨髓瘤(MM)患者临床相关指标和临床分期与预后关系,以期提高对该型MM的认识。方法:收集43例初诊为IgA型MM患者的临床资料,分析初诊时各临床指标与无进展生存时间(PFS)、总生存时间(OS)的关系。结果:单因素分析结果显示,对PFS有显著影响的是年龄>60岁,白蛋白≤30 g/L,化疗方案(非硼替佐米组),缓解情况(疾病稳定+疾病进展);对OS有显著影响的是年龄>60岁,白蛋白≤30 g/L,缓解情况(疾病稳定+疾病进展)。多因素分析结果显示,白蛋白≤30 g/L是影响患者PFS的独立预后不良因素;年龄>60岁、白蛋白≤30 g/L是影响患者OS的独立预后不良因素。结论:IgA型MM的预后与血清白蛋白、年龄有关,可以用来评估此类型患者的总体生存时间。
- IgA型多发性骨髓瘤 /
- 预后 /
- 总生存时间
Abstract: Objective:To explore the correlation between the prognosis of patients newly diagnosed with IgA type multiple myeloma (MM) and the level of their clinical staging and related indicators,so that we can improve the understanding of this type of MM.Method:The clinical data of 43 cases of IgA type MM initially diagnosed were collected.The relationship between the clinical indicators and the time of progression-free survival (PFS) and total survival (OS) was analyzed.Result:Univariate analysis showed that age >60 years old,albumin ≤30 g/L,chemotherapy regimen (non-borotezomib group) and remission (SD+PD) had significant effect on PFS.Significant effect on OS was seen in age >60 years old,albumin ≤30 g/L and remission (SD+PD).Multi-factor analysis showed that albumin ≤30 g/L was an independent prognostic factor influencing PFS of patients.Age>60 years old and albumin ≤30 g/L were the independent prognostic factors influencing OS of patients.Conclusion:The prognosis of IgA type MM is related to serum albumin and age,which can be used to evaluate the overall survival time of this type of patients.
- IgA type multiple myeloma /
- prognosis /
- total survival time

HTML全文

参考文献(10)

[1]	Daratumumab——breakthrough drug in multiple myeloma therapy[J].Postepy Hig Med Dosw (Online), 2014, 68:1352-1360.
[2]	朱婉秋, 陈文明.IMWG多发性骨髓瘤诊断标准解读[J].临床血液学杂志, 2017, 30 (7):507-509.
[3]	Rajkumar SV, Kumar S.Multiple myeloma:diagnosis and treatment[J].Mayo Clin Proc, 2016, 91:101-119.
[4]	Katzmann JA, Willrich MA, Kohlhagen MC, et al.Monitoring IgA multiple myeloma:immunoglobulin heavy/light chain assays[J].Clin Chem, 2015, 61:360-367.
[5]	Hose D, Reme T, Hielscher T, et al.Proliferation is a central independent prognostic factor and target for personalized and riskadapted treatment in multiple myeloma[J].Heamatologica, 2011, 96:87-95.
[6]	Ludwig H, Bolejack V, Crowley J, et al.Survival and years of life lost in different age cohorts of patients with multiple myeloma[J].J Clin Oncol, 2010, 28:1599-1605.
[7]	Lopes-Aguiar L, Delamain MT, Brito ABC, et al.VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens[J].Blood Cancer J, 2017, 7:e580.
[8]	Hashimoto S, Kuroha T, Yano T, et al.Thalidomide to bortezomib and dexamethasone for refractory multiple myeloma[J].Intern Med, 2016, 55:3025-3028.
[9]	吴文, 王焰, 高晓东, 等.PAD方案治疗初治多发性骨髓瘤的临床疗效[J].临床血液学杂志, 2017, 30 (3):210-213.
[10]	Younes M, Hachfi H, Hammouda F, et al.Survival prognosis factors in multiple myeloma[J].Tunis Med, 2014, 92:399-405.